Semparatide
Alternative Names: RS 66271Latest Information Update: 07 Jan 2021
At a glance
- Originator Roche Bioscience - UCB (JV)
- Class Peptides
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
- 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
- 09 Jun 2009 Semparatide licensed to Tokai Pharmaceuticals worldwide